Key result
Clinical registries for rheumatoid arthritis have provided significant insights into comparative effectiveness, long-term drug utilization, and risks for malignancies and infections.
Clinical registries in rheumatoid arthritis provide crucial real-world data on long-term safety, comparative effectiveness, and drug utilization beyond clinical trials.
Rheumatoid arthritis (RA) is one of the most common rheumatic conditions, impacting quality of life on several domains. Major breakthroughs have been achieved over the past three decades in the management benefitting the patients' lives. With increasing as well as novel treatment options, clinical registries have been established and continuously evolve to portray patient characteristics, monitor disease activity of RA, effectiveness and safety of the novel compounds. The greatest insights derived from registries is our current knowledge on the risks for malignancies and infections but also extending our knowledge collected in clinical trials on comparative effectiveness, long-term drug utilisation and under-represented populations. Moreover, the possible evolution of registries involving Big Data and AI, and the increased focus on patient centredness is discussed.
No takes yet. Share an insight, caveat, or question.
Studenic et al. (2024) conducted a review in Rheumatoid arthritis. Clinical registries was evaluated. Clinical registries for rheumatoid arthritis have provided significant insights into comparative effectiveness, long-term drug utilization, and risks for malignancies and infections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: